SULFONYLUREAS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS TODAY. IS THERE A PROSPECT?
- Authors: Kononenko I.V.1, Smirnova O.M.1, Smirnova OM1, Kononenko IV1
-
Affiliations:
- Issue: No 3 (2012)
- Pages: 34-42
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/279283
- ID: 279283
Cite item
Full Text
Abstract
Despite significant advances in the study of the pathophysiology of type 2 diabetes mellitus and numerous publications in its treatment, there is a large gap between well-established recommendations for its treatment and authentically known remote results of long-term use of drugs. The article analyzes the results of numerous studies on the efficacy and safety of different groups of antihyperglycemic drugs and their comparisons, as well as algorithms for their administration. Common point of view, however, has not yet developed. In all diabetes congresses and in the literature different recommendations are discussed, but the issue of positioning of certain drugs is still open.
About the authors
Irina Vladimirovna Kononenko
Ol'ga Mikhaylovna Smirnova
O M Smirnova
I V Kononenko
References
- The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
- United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
- Мельникова О.Г. Британское проспективное исследование сахарного диабета (UKPDS) - результаты 30-летнего наблюдения больных сахарным диабетом 2 типа // Сахарный диабет 2008. № 4. С. 90-1.
- ACCORD Study Group. N Engl J Med 2008;358:2545-49.
- Patel A, MacMahon S, Chalmers J, et al. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72.
- Nathan DM, Buse JB, Davidson MB, et al. Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963-72.
- Nathan DM, Buse JB, Davidson MB, et al. American Diabetes Association; European Association for the Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203.
- Rodbard HW, Jellinger PS, Davidson JA, еt al. Statement by an American Association of Clinical Endocrinologists / American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control. Endocr Pract 2009;15(6):540-59.
- Дедов И.И., Шестакова М.В., Аметов А.С., Анциферов М.Б. и др. Проект "Консенсус совет экспертов Российской ассоциации эндокринологов (РАЭ) по инициации и интенсификации сахароснижающей терапии СД 2 типа" // Сахарный диабет 2011. № 1. С. 98-108.
- Алгоритм специализированной медицинской помощи больным сахарным диабетом / Под ред. И.И. Дедова, М.В. Шестаковой. 5-е изд. доп. М., 2011.
- Ashcroft FM, Gribble FM. Sulfonilurea stimulation of insulin secretion: lessons from studies of cloned channels. J. Diabetes Compl 2000;12:2182-88.
- Полторак В.В., Горбенко Н.И., Горшунская М.Ю. Блокада КATP каналов препаратами сульфонилмочевины и кардиоваскулярная безопасность у больных сахарным диабетом 2 типа // Украинский медицинский вестник 2002. № 32.
- Maddock HL, Siedlecka SM, Yellon DM. Myocardial protection from either ischemic preconditioning or nicorandil is not blocked by gliclazide. Cardiovasc Drugs Ther 2004;18:113-19.
- Johnsen SP, Monster TBM, Olsen ML, et al. Risk and short-term prognosis of Myocardial infarction among users of antidiabetic drugs. Am J of Ther 2006;13(2):134-40.
- O'Brien RC, Luo M, Balazs N, Mercuri J. In-vitro and in-vivo antioxidant properties of gliclazide. J Diabetes Complications 2000;14:201-06.
- Ashcroft FM, Gribble FM. ATP sensitive K+ channels and insulin secretion: their role in health and disease. Diabetologia 1999;42:903-19.
- Kristiansen SB, et al. Diabetologia 2011;54:451-58.
- Esposito K, Cozzolino D, Maiorino MI, et al. Diabetes Obes Metab 2011;14/ doi:10/1111/j.1463-1326.2011.01380.x/.
Supplementary files
